Elevated Serum MMA of 358 nmol/L Indicates Vitamin B12 Deficiency
A serum methylmalonic acid (MMA) level of 358 nmol/L is elevated and confirms functional vitamin B12 deficiency, requiring immediate initiation of B12 replacement therapy. 1
Clinical Significance
Your MMA level of 358 nmol/L falls just above the upper limit of normal (reference range: 75-378 nmol/L per 2, or up to 331 nmol/L per 3). This elevation indicates impaired cellular B12 function even if your serum B12 levels appear normal or indeterminate. MMA is a metabolite that accumulates when there is insufficient B12 to convert methylmalonyl-CoA to succinyl-CoA, making it a highly sensitive functional marker of tissue B12 status 4.
Why This Matters
- 98.4% of patients with confirmed B12 deficiency have elevated MMA 4, making this one of the most reliable confirmatory tests
- Normal serum B12 levels can be misleading—patients can have functional B12 deficiency with normal serum B12 5, 6
- In one study, 37% of patients with low serum B12 (<200 pmol/L) had normal MMA, ruling out true deficiency 2
- Conversely, 11% of patients with neurological symptoms and normal serum B12 had elevated MMA, identifying otherwise missed deficiency 5
Immediate Next Steps
1. Initiate B12 Replacement Therapy Now
Do not delay treatment while investigating the underlying cause. The 2024 NICE guidelines 1 recommend starting replacement therapy based on confirmed deficiency (which your MMA level establishes).
Treatment regimen depends on neurological involvement:
- With neurological symptoms: Intramuscular hydroxocobalamin 1000 mcg on alternate days until symptom improvement
- Without neurological symptoms: Intramuscular hydroxocobalamin 1000 mcg three times weekly for 2 weeks, then maintenance
2. Assess for Neurological Manifestations
Look specifically for:
- Peripheral neuropathy (paresthesias, numbness)
- Subacute combined degeneration of the spinal cord (gait disturbance, proprioception loss)
- Cognitive changes or memory impairment
- Psychiatric symptoms (depression, psychosis)
Critical pitfall: Neurological damage can be irreversible if treatment is delayed. Three of five patients in one study showed documented neurological improvement with treatment 5, emphasizing the importance of early intervention.
3. Identify the Underlying Cause
Investigate risk factors per NICE 2024 1:
Dietary/absorption issues:
- Strict vegan/vegetarian diet
- Pernicious anemia (check intrinsic factor antibodies, parietal cell antibodies)
- Atrophic gastritis
- Celiac disease or inflammatory bowel disease
- Prior gastric surgery
Medication-induced:
- Metformin (most common)
- Proton pump inhibitors or H2 receptor antagonists
- Colchicine
- Phenobarbital, pregabalin, or primidone
4. Confirm Response to Treatment
Recheck MMA after 2-3 months of treatment. In one case report, MMA decreased from 2,920 nmol/L to 215 nmol/L after B12 saturation, confirming functional deficiency 6. In another study, 11 of 12 treated patients showed significant MMA decrease below 0.37 μmol/L (370 nmol/L) 5.
Important Caveats
False elevations of MMA can occur with:
- Renal insufficiency (check creatinine)
- Hypovolemia
- These accounted for most false-positive MMA elevations in folate-deficient patients 4
Do not recheck B12 levels after starting treatment—they will be artificially elevated and uninformative.
Evidence Quality Note
The 2024 NICE guidelines 1 acknowledge that MMA testing recommendations are based on "very low certainty evidence" and guideline committee experience. However, the research evidence consistently demonstrates MMA's superior sensitivity (98.4%) and specificity for functional B12 deficiency 4. The cost-effectiveness analysis showed MMA testing before treatment has an incremental cost-effectiveness ratio of £3,946 per quality-adjusted life year 1, supporting its use despite higher costs.
Your MMA level of 358 nmol/L, while borderline, should prompt treatment given the high stakes of untreated B12 deficiency (irreversible neurological damage) and the safety of B12 replacement therapy.